Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer

Inclusion Criteria: Histologically- or cytologically-confirmed diagnosis of stage IIIB or IV Non-Small Cell Lung Cancer Received only one prior treatment (not including radiation) Measurable disease per Response Evaluation Criteria in Solid Tumors Group (RECIST) guidelines Life expectancy of ≥ 4 months Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate hematologic, renal and hepatic function Serum-fasting cholesterol ≤ 300 mg/dL Serum-fasting triglycerides ≤ 2.5 X ULN Exclusion Criteria: Brain metastases requiring treatment History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline Systemic chemotherapy, radiotherapy, hormonal therapy or immunotherapy within 30 days before enrollment Prior epidermal growth factor receptor targeting agents with the exception of the small molecule EGFr tyrosine kinase inhibitors Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short serum half-life (less than 1 week) within 30 days before enrollment, or prior experimental or approved proteins/antibodies with longer serum half-life within 6 weeks before enrollment Prior therapy with sirolimus, sirolimus analogs Immunosuppressive agents within 28 days before enrollment